Heparin-induced thrombocytopenia: diagnosis and management.
Warkentin
Theodore E
TE
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. twarken@mcmaster.ca
D000925:Anticoagulants / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D001022:Aortic Valve Insufficiency / Q000601:surgery; D001120:Arginine / Q000031:analogs & derivatives; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D005260:Female; D005385:Fingers / Q000098:blood supply; D019918:Heart Valve Prosthesis Implantation; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D006629:Hirudins / Q000276:immunology; D006801:Humans; D007511:Ischemia / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D009336:Necrosis; D010875:Pipecolic Acids / Q000276:immunology / Q000627:therapeutic use; D015539:Platelet Activation / Q000276:immunology; D010978:Platelet Factor 4 / Q000276:immunology; D011183:Postoperative Complications / Q000517:prevention & control; D011928:Raynaud Disease / Q000150:complications; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D013927:Thrombosis / Q000517:prevention & control; D014034:Toes / Q000098:blood supply; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D001323:Autoantibodies; D006629:Hirudins; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D010978:Platelet Factor 4; D014859:Warfarin; D006493:Heparin; D001120:Arginine; C031942:argatroban; C083544:lepirudin